Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Flu drug trial pulled before it even started

NCT ID NCT01224795

Symptom relief Sponsor: BioCryst Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study planned to test a single IV dose of peramivir against placebo in teens and adults with uncomplicated flu. The goal was to see if it could shorten flu symptoms like cough, sore throat, and fever. However, the trial was withdrawn before any participants were enrolled, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
peramivir
What this could lead to
If it worked, this could provide a faster way to ease flu symptoms for people who need IV treatment.
What could go wrong
The trial was withdrawn before enrolling anyone, so we have no results. Even if run, it might not show meaningful benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Start date

Oct 2010

Finished

Nov 2010

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and non-pregnant female subjects age ≥12 years. * Test positive for influenza A or B by Rapid Antigen Test (RAT) performed with a commercially available test on an adequate anterior nasal specimen in accordance with the manufacturer's instructions. * Presence of at least one respiratory symptom (cough, sore throat, or nasal symptoms) of at least moderate severity. * Presence of at least one constitutional symptom (myalgia \[aches and pains\], headache,feverishness, or fatigue) of at least moderate severity. * Onset of symptoms no more than 36 hours before presentation for screening. * Written informed consent/assent. Exclusion Criteria: * Women who are pregnant or breast-feeding. * Employees of the study site, or immediate family members of study site employees. * Presence of clinically significant signs of acute respiratory distress. * History of severe chronic obstructive pulmonary disease (COPD) or severe persistent asthma. * History of heart failure or angina requiring daily pharmacotherapy with symptoms consistent with New York Heart Association Class III or IV functional status within the past 12 months. * History of chronic renal impairment requiring hemodialysis and/or known or suspected to have moderate or severe renal impairment (actual or estimated creatinine clearance \<50 mL/min). * Clinical evidence of worsening of any chronic medical condition (temporally associated with the onset of symptoms of influenza) which, in the investigator's opinion, indicates that such finding(s) could represent complications of influenza. * Current clinical evidence, including clinical signs and/or symptoms consistent with otitis media,bronchitis, sinusitis and/or pneumonia, or active bacterial infection of any body site that requires therapy with oral or systemic antibiotics. * Presence of immunocompromised status due to chronic illness, previous organ transplant, or use of immunosuppressive medical therapy which would include oral or systemic treatment with \> 10 mg ic treatment with \> 10 mg prednisone or equivalent on a daily basis within 30 days of screening. * Presence of known HIV infection with a CD4 count \<350 cell/mm3. * Receipt of any dose of rimantadine, amantadine, zanamivir, or oseltamivir in the 7 days prior to screening. * Immunization against influenza with live attenuated virus vaccine (FluMist®) in the previous 21 days. * History of alcohol abuse or drug addiction within 1 year prior to admission in the study. * Participation in a previous study of intramuscular or intravenous peramivir, or previous exposure to peramivir. * Participation in a study of any investigational drug or device within the last 30 days. * Presence of any pre-existing illness that, in the opinion of the investigator, would place the subject at an unreasonably increased risk through participation in this study. * Presence of any pre-existing illness that in the opinion of the investigator would make the subject unable to comply with the protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Influenza are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

influenza

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Influenza

Contacts and locations

Locations

  • Study site

    Birmingham, Alabama, United States

  • Study site

    Hot Springs, Arkansas, United States

  • Study site

    Jonesboro, Arkansas, United States

  • Study site

    Little Rock, Arkansas, United States

  • Study site

    Mountain Home, Arkansas, United States

  • Study site

    Anaheim, California, United States

  • Study site

    Buena Park, California, United States

  • Study site

    Chino, California, United States

  • Study site

    Dinuba, California, United States

  • Study site

    Garden Grove, California, United States

  • Study site

    Lincoln, California, United States

  • Study site

    Los Angeles, California, United States

  • Study site

    Oceanside, California, United States

  • Study site

    Palm Springs, California, United States

  • Study site

    Port Hueneme, California, United States

  • Study site

    Sacramento, California, United States

  • Study site

    San Diego, California, United States

  • Study site

    Tustin, California, United States

  • Study site

    West Covina, California, United States

  • Study site

    Boulder, Colorado, United States

  • Study site

    Centennial, Colorado, United States

  • Study site

    Wheat Ridge, Colorado, United States

  • Study site

    Milford, Connecticut, United States

  • Study site

    Brooksville, Florida, United States

  • Study site

    Coral Gables, Florida, United States

  • Study site

    Cutler Bay, Florida, United States

  • Study site

    Daytona Beach, Florida, United States

  • Study site

    Edgewater, Florida, United States

  • Study site

    Gainesville, Florida, United States

  • Study site

    Hialeah, Florida, United States

  • Study site

    Jacksonville, Florida, United States

  • Study site

    Miami, Florida, United States

  • Study site

    South Miami, Florida, United States

  • Study site

    West Palm Beach, Florida, United States

  • Study site

    Stockbridge, Georgia, United States

  • Study site

    Boise, Idaho, United States

  • Study site

    Aurora, Illinois, United States

  • Study site

    Bloomingdale, Illinois, United States

  • Study site

    Chicago, Illinois, United States

  • Study site

    Peoria, Illinois, United States

  • Study site

    South Bend, Indiana, United States

  • Study site

    Dubuque, Iowa, United States

  • Study site

    Arkansas City, Kansas, United States

  • Study site

    Lenexa, Kansas, United States

  • Study site

    Bardstown, Kentucky, United States

  • Study site

    Hazard, Kentucky, United States

  • Study site

    Paducah, Kentucky, United States

  • Study site

    Baton Rouge, Louisiana, United States

  • Study site

    Shreveport, Louisiana, United States

  • Study site

    Bangor, Maine, United States

  • Study site

    Hollywood, Maryland, United States

  • Study site

    Rockville, Maryland, United States

  • Study site

    Brockton, Massachusetts, United States

  • Study site

    Fall River, Massachusetts, United States

  • Study site

    Washington, Missouri, United States

  • Study site

    Bozeman, Montana, United States

  • Study site

    Fremont, Nebraska, United States

  • Study site

    Lincoln, Nebraska, United States

  • Study site

    Omaha, Nebraska, United States

  • Study site

    Albuquerque, New Mexico, United States

  • Study site

    Camillus, New York, United States

  • Study site

    Raleigh, North Carolina, United States

  • Study site

    Winston-Salem, North Carolina, United States

  • Study site

    Fargo, North Dakota, United States

  • Study site

    Akron, Ohio, United States

  • Study site

    Dayton, Ohio, United States

  • Study site

    Wadsworth, Ohio, United States

  • Study site

    Owasso, Oklahoma, United States

  • Study site

    Bend, Oregon, United States

  • Study site

    Medford, Oregon, United States

  • Study site

    Hatfield, Pennsylvania, United States

  • Study site

    Philadelphia, Pennsylvania, United States

  • Study site

    Scotland, Pennsylvania, United States

  • Study site

    Cranston, Rhode Island, United States

  • Study site

    Cumberland, Rhode Island, United States

  • Study site

    Johnston, Rhode Island, United States

  • Study site

    Easley, South Carolina, United States

  • Study site

    Greenville, South Carolina, United States

  • Study site

    Bristol, Tennessee, United States

  • Study site

    Arlington, Texas, United States

  • Study site

    Austin, Texas, United States

  • Study site

    Beaumont, Texas, United States

  • Study site

    Bryan, Texas, United States

  • Study site

    Dallas, Texas, United States

  • Study site

    Fort Worth, Texas, United States

  • Study site

    Georgetown, Texas, United States

  • Study site

    Houston, Texas, United States

  • Study site

    Lake Jackson, Texas, United States

  • Study site

    North Richland Hills, Texas, United States

  • Study site

    San Antonio, Texas, United States

  • Study site

    Spring, Texas, United States

  • Study site

    Salt Lake City, Utah, United States

  • Study site

    South Jordan, Utah, United States

  • Study site

    West Jordan, Utah, United States

  • Study site

    Arlington, Virginia, United States

  • Study site

    Charlottesville, Virginia, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.